Home » Novo Nordisk Licenses Human Monoclonal Antibody From ZymoGenetics
Novo Nordisk Licenses Human Monoclonal Antibody From ZymoGenetics
Novo Nordisk and ZymoGenetics have signed an agreement where Novo Nordisk
in-licenses a fully human anti-IL21 monoclonal antibody, or IL-21 mAb, developed by ZymoGenetics, as well as broad intellectual property rights covering
IL-21 mAb and the development of other IL-21 antibodies.
American Chronicle
American Chronicle
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May